Drug Developed for Spinal Cord Injuries Shows Promise Against Alzheimer’s DNA Damage and Inflammation

Researchers have found that a medication originally created to treat spinal cord injuries can also address key aspects of Alzheimer’s disease, including DNA damage and brain inflammation. The compound, which has already undergone initial safety trials in humans, demonstrates the ability to repair damaged DNA and reduce inflammatory markers in neural tissue. By targeting these underlying mechanisms, the drug offers a potential route to disease‑modifying treatments rather than merely managing symptoms. The early human safety data suggest a streamlined development timeline, potentially accelerating the availability of root‑cause therapies for patients with Alzheimer’s. This approach could reduce the time required to bring new Alzheimer’s therapies to clinical use.